Medical Xpress June 5, 2025
GLP-1 (glucagon-like peptide-1) therapies can be powerful tools in managing obesity, with patients taking these medications seeing weight reductions of 5%–18% in clinical trials, along with increased metabolism and benefits to their overall heart health. However, GLP-1s can come with challenges, including gastrointestinal side effects, risk of micronutrient deficiencies, muscle and bone loss, poor long-term follow-through with weight regain if stopped, and high costs.
A thoughtful and comprehensive nutrition and lifestyle program can help address these challenges and increase the efficacy and cost-effectiveness of GLP-1s.
Dariush Mozaffarian, cardiologist and director of the Food is Medicine Institute at the Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy at Tufts University, recently served as lead chair and author...
Today's Sponsors
Today's Sponsor